E. Hogg

发表

Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial

A. Zolopa, V. Veloso, M. Hosseinipour, 2016, The Lancet.

Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study.

M. Hughes, R. Schooley, R. Gross, 2019, The lancet. HIV.

Male sex and obesity are associated with residual plasma HIV-1 viremia in persons on long-term antiretroviral therapy.

J. Mellors, R. Bosch, A. Collier, 2020, The Journal of infectious diseases.

Association of Male Sex and Obesity With Residual Plasma Human Immunodeficiency Virus 1 Viremia in Persons on Long-Term Antiretroviral Therapy

J. Mellors, R. Bosch, A. Collier, 2020, The Journal of Infectious Diseases.

PD-1HI T cells are associated with lower hiv-specific immune responses despite long-term antiretroviral therapy.

J. Mellors, R. Bosch, C. Rinaldo, 2020, AIDS.

Persistent HIV-infected cells in cerebrospinal fluid are associated with poorer neurocognitive performance.

J. Mellors, R. Bosch, C. Rinaldo, 2019, The Journal of clinical investigation.

Cumulative Antiretroviral Exposure Measured in Hair Is Not Associated With Measures of HIV Persistence or Inflammation Among Individuals on Suppressive ART

J. Mellors, R. Bosch, C. Fletcher, 2018, The Journal of infectious diseases.

Early Antiretroviral Therapy Reduces AIDS Progression/Death in Individuals with Acute Opportunistic Infections: A Multicenter Randomized Strategy Trial

A. Zolopa, W. Powderly, I. Sanne, 2009, PloS one.

Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV

S. Swindells, G. McComsey, P. Tebas, 2007, AIDS.

Assessing whether isoniazid is essential during the first 14 days of tuberculosis therapy: a phase 2a, open-label, randomised controlled trial.

W. Bishai, A. Diacon, S. Swindells, 2020, The Lancet. Microbe.

Fish Oil and Fenofibrate for the Treatment of Hypertriglyceridemia in HIV-Infected Subjects on Antiretroviral Therapy:

C. Fichtenbaum, E. Acosta, D. Kitch, 2009 .

Two-way mobile phone intervention compared with standard-of-care adherence support after second-line antiretroviral therapy failure: a multinational, randomised controlled trial.

M. Hughes, R. Gross, J. Mellors, 2019, The Lancet. Digital health.

Biomarkers Associated with Death After Initiating Treatment for Tuberculosis and HIV in Patients with Very Low CD4 Cells

D. Havlir, U. Lalloo, V. Veloso, 2018, Pathogens & immunity.

Amdoxovir versus Placebo with Enfuvirtide plus Optimized Background Therapy for HIV-1-Infected Subjects Failing Current Therapy (Aactg A5118)

S. Hammer, D. Kuritzkes, J. Gerber, 2005, Antiviral therapy.

Long-term Outcomes in a Large Randomized Trial of HIV-1 Salvage Therapy: 96-week Results of AIDS Clinical Trials Group A5241 (OPTIONS).

K. Tashima, C. Fichtenbaum, L. Smeaton, 2019, The Journal of infectious diseases.

Long-term Outcomes in a Large Randomized Trial of HIV-1 Salvage Therapy : 96-week Results of AIDS Clinical Trials Group A 5241 ( OPTIONS )

K. Tashima, C. Fichtenbaum, --Manuscript Draft, 2019 .

Antiretroviral therapies in women after single-dose nevirapine exposure.

M. Hughes, R. Schooley, J. Mellors, 2010, The New England journal of medicine.

SEX DIFFERENCES IN OUTCOMES FOR INDIVIDUALS PRESENTING FOR THIRD-LINE ANTIRETROVIRAL THERAPY.

M. Hughes, R. Gross, A. Collier, 2020, Journal of acquired immune deficiency syndromes.

Antiretroviral hair levels, self-reported adherence, and virologic failure in second-line regimen patients in resource-limited settings

K. Ruxrungtham, R. Gross, S. Kerr, 2021, AIDS.

Risk Factor Analyses for Immune Reconstitution Inflammatory Syndrome in a Randomized Study of Early vs. Deferred ART during an Opportunistic Infection

M. Lederman, A. Zolopa, P. Grant, 2010, PloS one.

The use of β-D-2,6-diaminopurine dioxolane with or without mycophenolate mofetil in drug-resistant HIV infection

J. Mellors, D. Margolis, C. Fletcher, 2007, AIDS (London).

Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study.

D. Havlir, S. Swindells, F. Aweeka, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Timing of antiretroviral therapy for HIV-1 infection and tuberculosis.

Lerato Mohapi, Ian Sanne, Peter Mugyenyi, 2011, The New England journal of medicine.

Linked dual-class HIV resistance mutations are associated with treatment failure.

M. Hughes, R. Schooley, J. Mellors, 2019, JCI insight.

Fish Oil and Fenofibrate for the Treatment of Hypertriglyceridemia in HIV-Infected Subjects on Antiretroviral Therapy: Results of ACTG A5186

C. Fichtenbaum, E. Acosta, D. Kitch, 2008, Journal of acquired immune deficiency syndromes.

Third‐line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource‐limited settings: ACTG A5288 strategy trial

R. Schooley, R. Gross, J. Mellors, 2022, Journal of the International AIDS Society.

Predictors of virologic outcome among people living with HIV who continue a protease inhibitor-based antiretroviral regimen following virologic failure with no or limited resistance

R. Gross, J. Mellors, A. Collier, 2023, AIDS Research and Therapy.

Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation

J. Mellors, R. Bosch, C. Rinaldo, 2017, PLoS pathogens.

Impact of Larger Sputum Volume on Xpert® MTB/RIF Assay Detection of Mycobacterium tuberculosis in Smear-Negative Individuals with Suspected Tuberculosis

D. Alland, I. Sanne, G. Mazurek, 2017, Journal of clinical medicine.

Isoniazid Adherence Reduces Mortality and Incident Tuberculosis at 96 Weeks Among Adults Initiating Antiretroviral Therapy With Advanced Human Immunodeficiency Virus in Multiple High-Burden Settings

U. Lalloo, V. Veloso, C. Kityo, 2022, Open forum infectious diseases.

Renal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapine

M. Hughes, A. Siika, S. Lockman, 2014, AIDS.

Excellent retention, virologic and clinical outcomes after transitioning from an antiretroviral treatment clinical trial to locally-provided care and treatment in Africa

A. Siika, S. Lockman, J. Currier, 2017 .

No Evidence for an Association between Statin Use and Lower Biomarkers of HIV Persistence or Immune Activation/Inflammation During Effective ART

J. Mellors, R. Bosch, C. Rinaldo, 2019, Journal of acquired immune deficiency syndromes.

Nevirapine- Versus Lopinavir/Ritonavir-Based Initial Therapy for HIV-1 Infection among Women in Africa: A Randomized Trial

M. Hughes, R. Schooley, J. Mellors, 2012, PLoS medicine.

Cardiovascular Disease Risk Factors in HIV-Infected Women After Initiation of Lopinavir/Ritonavir- and Nevirapine-Based Antiretroviral Therapy in Sub-Saharan Africa: A5208 (OCTANE)

M. Hughes, S. Lockman, J. Currier, 2014, Journal of acquired immune deficiency syndromes.

Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients: a randomized trial.

C. Flexner, R. Gross, T. Flanigan, 2009, Archives of internal medicine.

Brief Report: No Differences Between Lopinavir/Ritonavir and Nonnucleoside Reverse Transcriptase Inhibitor–Based Antiretroviral Therapy on Clearance of Plasmodium falciparum Subclinical Parasitemia in Adults Living With HIV Starting Treatment (A5297)

V. A. Stewart, R. Schooley, F. Ssali, 2021, Journal of acquired immune deficiency syndromes.

Participant Perspectives and Experiences Following an Intensively Monitored Antiretroviral Pause (IMAP) in the United States: Results from the AIDS Clinical Trials Group (ACTG) A5345 Biomarker Study.

Davey M. Smith, J. Simoni, S. Deeks, 2022, AIDS research and human retroviruses.

Diverse HIV-1 Drug Resistance Profiles at Screening for ACTG A5288: A Study of People Experiencing Virologic Failure on Second-line ART in Resource Limited Settings.

M. Hughes, R. Gross, J. Mellors, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Diverse Human Immunodeficiency Virus–1 Drug Resistance Profiles at Screening for ACTG A5288: A Study of People Experiencing Virologic Failure on Second-line Antiretroviral Therapy in Resource-limited Settings

R. Gross, J. Ritz, B. Grinsztejn, 2020 .

Novel Dosing Strategies Increase Exposures of the Potent Antituberculosis Drug Rifapentine but Are Poorly Tolerated in Healthy Volunteers

K. Dooley, S. Dorman, J. Park, 2015, Antimicrobial Agents and Chemotherapy.

Empiric Tuberculosis Therapy versus Isoniazid in Advanced HIV-infected Adult Outpatients Initiating Antiretroviral Therapy : a Multi-Country Randomized Controlled Trial

V. Veloso, M. Hosseinipour, J. Kumwenda, 2016 .